Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.
Guardant is alleging that Foundation's advertising of its own products has harmed both Guardant and cancer patients.
The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.
Guardant will provide its Guardant360 liquid biopsy cancer assay to Pfizer's oncology business unit for use in clinical trials.
The belief among genomics experts that one day drugs would be given based on genomic abnormalities that cut across tumor types became reality this week.
Guardant said Guardant360 is the first liquid biopsy permitted by New York's CLEP, and the approval means the test can be ordered in all 50 states.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
The money will fund a new plan to sequence tumor DNA from more than 1 million cancer patients. The firm also announced a new JV in Asia, the Middle East, and Africa.
The Palo Alto-based firm plans to use the money to further validate its non-invasive, early cancer detection technology.
MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.
NPR reports that Turkish high school students will no longer study evolution.
Researchers report they sequenced and identified plant species in an "al fresco" laboratory.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.